You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

October 25, 2016

Effects of the TPP on Vietnam’s Pharmaceutical Industry

Subscribe to Updates
Vietnam Pharma Update

On February 4, 2016, Vietnam and 11 other countries signed the Trans-Pacific Partnership (TPP). The TPP includes Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, the United States, Vietnam, and Singapore—countries which represent 36 percent of global GDP and more than 25 percent of world trade. Though the prospects of a quick and smooth ratification of the treaty have dimmed considerably, thanks to election-year politicization in the United States, if and when the TPP is finally ratified by its various participants, it will have a major impact on business in Vietnam—including the pharmaceutical industry.

The TPP will affect the pharmaceutical industry largely through its investment protections and intellectual property regime. Like other free-trade agreements, the TPP promotes foreign investment by requiring its member states to provide protections over investments originating from other TPP member countries. Importantly, intellectual property rights are considered a “covered investment” under the TPP. In other words, Vietnam is obligated to protect a pharmaceutical company’s IP rights in accordance with the TPP. In addition to these investment protections, the TPP also contains an entire subchapter dedicated to the pharmaceutical industry, including the treatment of patents.

Investment Protections

While most of the investment protection under the TPP would apply to all companies equally, pharmaceutical companies should pay particular attention to the following.

National Treatment and Most-Favored Nation Treatment. The TPP requires Vietnam to treat investors from other TPP member states (TPP Investors) the same way it would treat domestic investors in similar circumstances. In other words, Vietnam is required to give “national treatment” to TPP Investors. In addition, Vietnam must treat such covered investments the same way it would treat locally owned projects. The TPP also requires Vietnam not to discriminate against any foreign investor. For example, if an American pharmaceutical company owns a patent in Vietnam, that patent must be treated the same way as if a Vietnamese party held the patent. 

Expropriation. The TPP prohibits member states from expropriating investments. In other words, Vietnam would generally be prohibited from expropriating or nationalizing a pharmaceutical company’s IP rights. However, expropriation is allowed if it is for a “public purpose,” such as compulsory patent licensing in a public health emergency. In such case, Vietnam must promptly provide compensation to the investor that is equivalent to market value. The TPP further mandates that any expropriation must be done without discrimination.

Performance Requirements. The TPP prohibits Vietnam from requiring an investment project to use or implement certain “preferred” commitments or content. For example, Vietnam cannot enact legislation requiring a foreign pharmaceutical company to use only locally sourced materials or technology in its toll manufacturing, or to export a specific percentage of goods. Other prohibitions include forcing an investor to adopt a specific royalty rate under a license contract or a specific term of a license contract.

Important exceptions to this provision exist. The license restrictions do not apply to license agreements between a foreign investor and the Vietnamese government. In addition, the government is allowed to mandate performance requirements with regard to government procurement, certain investment privileges and benefits, and preferential tariffs or quotas. Other general exceptions also apply, such as legislation to protect human and environmental health.

Patents

Under Article 5.3 of Vietnam’s Law on Intellectual Property, if a regulation in an international convention of which Vietnam is a member differs from the respective regulation of the IP law, then the regulation in the convention would apply. Based on this, the Law on Intellectual Property will likely be adjusted to be consistent with the TPP. The following articles in the current regulations are not consistent with the respective regulations of the TPP:

Patentable Subject Matter. Under the TPP, patents are available for “use inventions,” that is, those claiming at least one of the following: new uses of a known product, new methods of using a known product, or new processes of using a known product. A member state may limit those new processes to those that do not claim the use of the product. Currently, the Vietnam Patent Office rejects use inventions in general, though it lacks convincing legal grounds. In light of the TPP, Vietnam’s Patent Office should change its treatment of use inventions. However, it is unclear—even with the change—whether new indications or new methods, such as new dosing, will be patentable.

Patent Term Adjustment for Patent Office Delays. According to the TPP, a patent term can be adjusted to compensate for unreasonable delays in a member state’s issuance of patents. The transition period is five years, which can be extended for up to one additional year, meaning that it could become effective in 2023 or 2024. This issue is not addressed in Vietnam’s current regulations.

Data Protection for Drugs. The provisions of the TPP on data protection for drugs differ from current Vietnamese law. Under the current regulations, within five years from the date of marketing authorization of the data-protected drug, no marketing authorization can be granted for other dossiers referring to the protected trial data. The TPP also provides a period of at least five years from the date of marketing authorization during which a third party cannot market a product on the basis of: (1) protected data; or (2) the marketing approval granted. Therefore, there could be some adjustments in the applicable laws of Vietnam related to data protection for drugs to make the data protection more reliable in practice. The transition period is ten years, which can be extended for up to two additional years, meaning that it could become effective in 2028 or 2030.

Outlook

The TPP is expected to create new business opportunities in Vietnam for pharmaceutical companies. The investment protections will reduce risk and increase confidence, which will add to investment inflows. Pharmaceutical companies would also have increased predictability and protections with respect to their IP rights. Both Vietnam and pharmaceutical firms will benefit.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Corporate/M&A

Intellectual Property

Regulatory Affairs

Location

RELATED INSIGHTS​ 

August 27, 2021
The process of registering pesticide products in Myanmar has been slowed significantly by regulatory challenges since the enactment of the Pesticide Law in 2016. In some cases, the whole process can take almost three years. Nonetheless, this stringent and time-consuming process has been functioning smoothly, and Tilleke & Gibbins has successfully received approvals from the Pesticide Registration Board (PRB) despite the ongoing COVID-19 pandemic and state of emergency in the country. Overview Since its enactment, the Pesticide Law of 2016 has governed the regulation of local and imported pesticides under the oversight of the Plant Protection Division (PPD) and the joint secretary of the PRB. All foreign and domestic companies (including subsidiaries and joint ventures) looking to have their agricultural or household pest control products imported into Myanmar must first provide the products’ complete formulas and lists of active ingredients to the PPD, and apply for a pesticide registration certificate. Applications should be supported by a letter of consent from the manufacturer and various other technical documents and requirements. Experts at the PRB will review the technical dossier and inform the applicant if any re-submissions are required. Key Considerations One common cause of delay in the registration process is the requirement to submit both English and Myanmar translations of proposed labels to the PRB. Because the PRB takes a restrictive view of these labels and their translations, having the labels initially reviewed by a local regulatory expert familiar with the requirements will streamline the process by flagging potential issues for correction before submission to the PRB. After document submission is complete, the next stage of the process is further lab testing according to requirements set out by the Myanmar Pesticide Law. Applicants will need to supply the formulated product in an amount sufficient for carrying out supervised trials and
Read More
August 26, 2021
The Ministry of Health of Vietnam recently issued Circular No. 10/2021/TT-BYT dated June 30, 2021, stipulating the list of substances prohibited from use in the production and trading of health supplements (“Circular 10”). Circular 10 will come into effect on September 1, 2021. Accordingly, substances found on the following lists will be prohibited from use in health supplements: The list of drugs and drug materials prohibited from importation and production found in Annex V of Decree No. 54/2017/ND-CP of the Government dated May 8, 2017, guiding the implementation of Law on Pharmacy (Decree 54). Lists promulgated with Decree No. 73/2018/ND-CP of the Government dated May 15, 2018, stipulating the list of narcotic substances and precursors, including: List I: Narcotic substances banned from use in healthcare and daily life, the use of which for analysis, testing, scientific research, and criminal investigation is subject to permission by competent authorities. List II: Narcotic substances restricted from analysis, testing, scientific research, criminal investigation, or healthcare as regulated by competent authorities. List III: Narcotic substances permitted in analysis, testing, scientific research, criminal investigation, healthcare, and veterinary medicine as regulated by competent authorities. List IVA: Essential precursors involved in forming the structure of narcotic substances. The list of narcotic active ingredients found in Annex I of Circular No. 20/2017/TT-BYT of the Ministry of Health, detailing articles of the Law on Pharmacy and Decree 54 related to drugs and drug materials under special control. The list of toxic drugs and toxic drug materials under Circular No. 06/2017/TT-BYT of the Ministry of Health dated May 3, 2017. Lists under Circular No. 42/2017/TT-BYT of the Ministry of Health dated November 13, 2017, stipulating the lists of toxic herbal materials, including: Annex I: List of toxic herbal materials of plant origin. Annex II: List of toxic herbal materials of
Read More
August 26, 2021
In April 2021, the Vietnamese government made public a draft decree to amend Decree No. 43/2017/ND-CP of the Government dated April 14, 2017, on goods labeling (“Decree 43”), which is the primary legislation in Vietnam on the labeling requirements for domestically circulating goods and imported goods. Some noteworthy differences between the draft and the current Decree 43 include the following: 1. Original labels for imported products For imported goods, the draft adds a requirement on compulsory information for original labels, which is not mentioned in Decree 43. In particular, the original product label for goods being imported to circulate on the Vietnam market must contain the following compulsory information in a foreign language or in Vietnamese before customs clearance: Product name; Name and address of the entities responsible for the products; Product origin or place where the final production stage to complete the product was conducted. (If this information is not presented on the original product label, it must be included in the import documents accompanying the product.) 2. Vietnamese labels for imported products Under the draft, if it is impossible to determine the product origin under rules/guidance on determining product origin in Vietnam, it is acceptable to instead indicate on the product label the place(s) where the final production stage to complete the product was conducted. 3. Nutritional information for food Instead of being optional information as mentioned in Decree 43, “nutritional value” is compulsory information on labels for some food products under the draft. The Ministry of Health will have a roadmap for carrying out nutritional labeling and will provide appropriate guidance to manufacturers and importers, as well as issue regulations on types of food that are partially or entirely exempt from declaration of nutritional value. The draft has not yet been finalized and is subject to
Read More